{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"3","upperLimit":"27","value":"11.5"},{"groupId":"OG001","lowerLimit":"16","upperLimit":"49","value":"30.8"},{"groupId":"OG002","lowerLimit":"5","upperLimit":"32","value":"15.4"},{"groupId":"OG003","lowerLimit":"39","upperLimit":"91","value":"70.0"},{"groupId":"OG004","lowerLimit":"45","upperLimit":"96","value":"77.8"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"9"}],"units":"Participants"}],"description":"Assessed by Common Terminology Criteria for Adverse Events version 4.0. The proportions of subjects with grade-3 or higher adverse events (all attributions) are presented with 90% exact binomial confidence intervals.","dispersionType":"90% Confidence Interval","groups":[{"description":"Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive high-dose radiation therapy QD over 10 days for up to 3 fractions.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"OG000","title":"NSCLC Arm A (Tremelimumab, Durvalumab, HD-RT)"},{"description":"Patients receive tremelimumab and durvalumab as in Arm C. Beginning at week 2, patients receive low-dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"OG001","title":"NSCLC Arm B (Tremelimumab, Durvalumab, LD-RT)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses.\n\nDurvalumab: Given IV\n\nTremelimumab: Given IV","id":"OG002","title":"NSCLC Arm C (Tremelimumab, Durvalumab)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Beginning at week 2, patients receive high-dose radiation therapy QD over 10 days for up to 3 fractions.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"OG003","title":"CRC Arm A (Tremelimumab, Durvalumab, HD-RT)"},{"description":"Patients receive tremelimumab IV and durvalumab IV over 60 minutes every 4 weeks for up to 16 weeks in the absence of disease progression or unacceptable toxicity. Patients then receive durvalumab IV over 60 minutes 4 weeks after last combination dose for up to 9 additional doses. Beginning at week 2, patients receive low-dose radiation therapy every 6 hours BID on weeks 2, 6, 10 and 14.\n\nDurvalumab: Given IV\n\nRadiation Therapy: Undergo radiation therapy\n\nTremelimumab: Given IV","id":"OG004","title":"CRC Arm B (Tremelimumab, Durvalumab, LD-RT)"}],"paramType":"NUMBER","populationDescription":"Participants who received at least one regimen of protocol therapy.","reportingStatus":"POSTED","timeFrame":"Up to 2 years","title":"Incidence of Grade 3-5 Adverse Events","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}